The minimum clinically important difference (MCID) is a threshold of improvement that is clinically relevant to the patient.
Future targeted randomized studies could further evaluate SSTS by addressing parameters such as "minimally important difference" and "threshold of improvement", as suggested recently by several working groups on patient reported outcomes on pain.
With newer treatments developed for RA it has become more commonplace in RA treatment studies to go beyond the minimal threshold of improvement (ACR20 response criteria) to include evaluations of treatment efficacy in terms of ACR50 and ACR70 response thresholds.
This patient experienced a downstaging to CCS class II.> Considering a threshold of improvement in perfusion of 5%%, based on an estimated error of measurement of 5%%, 10 (77 %) patients out of 13 with a better perfusion of the target segments improved in their CCS class, whereas, 3 (43 %) patients out of 7 without better perfusion of the target segments improved in their CCS class, too (Table 5).
As suggested by several authors, evaluations derived from patient reported outcomes on pain should be considered within a broader concept of "minimally important differences" and of "thresholds of improvement" and should be considered when evaluating success of interventions (Busse et al., 2015).
The results of this study provide potentially useful thresholds of improvement in PROs that go beyond the threshold of minimal importance established for these tools.
For example, analyses involving ACR-N showed that, as patients met higher thresholds of improvement on ACR-N there were incremental improvements in HRQoL and fatigue.
In order to identify clinically meaningful effects among individual patients, post hoc analyses of data from these trials were conducted using accepted definitions of response and remission that require more stringent thresholds of improvement.
Results of this study show considerable agreement between minimal thresholds of improvement established for PROs and clinical outcome measures used in RA treatment studies and provide thresholds to be considered in gauging the importance of a treatment effect that goes beyond what is considered as minimally important for PRO measures.
To visually assess the IBS-QOL total score, the cumulative proportion of patients meeting a certain change from Baseline to Week 12 was also plotted by treatment group and the proportion of patients meeting certain thresholds of improvement for Placebo and Eluxadoline 100 mg treatment groups were compared.
